DiaMedica Therapeutics (NASDAQ:DMAC) Issues Earnings Results

DiaMedica Therapeutics (NASDAQ:DMAC) issued its quarterly earnings data on Monday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01), Zacks reports.

DiaMedica Therapeutics Price Performance

DMAC stock traded up $0.22 during trading on Monday, reaching $5.99. The company had a trading volume of 106,512 shares, compared to its average volume of 69,604. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.82. The business has a 50 day moving average of $5.95 and a 200 day moving average of $5.08. The company has a market cap of $256.14 million, a P/E ratio of -10.70 and a beta of 1.52.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.